Immunocore/$IMCR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Immunocore

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Ticker

$IMCR
Primary listing

Industry

Biotechnology

Employees

493

ISIN

US45258D1054

Immunocore Metrics

BasicAdvanced
$1.6B
-
-$0.43
0.75
-

What the Analysts think about Immunocore

Analyst ratings (Buy, Hold, Sell) for Immunocore stock.

Bulls say / Bears say

Immunocore's KIMMTRAK achieved net revenues of $93.9 million in Q1 2025, marking a 33% year-over-year growth, indicating strong market adoption and potential for continued revenue expansion. (stocktitan.net)
The company maintains a robust cash position of $837.0 million as of March 31, 2025, providing substantial financial flexibility to support ongoing research and development initiatives. (stocktitan.net)
Immunocore is advancing multiple Phase 3 trials across various melanoma indications, with initial data readouts expected in 2026, potentially expanding its product portfolio and market reach. (stocktitan.net)
In Q1 2025, Immunocore reported a net income of $5.0 million, a significant improvement from a net loss of $24.4 million in the same period in 2024, but the company has a history of operating losses, which may raise concerns about consistent profitability. (stocktitan.net)
The company's research and development expenses increased to $214.38 million in FY 2024 from $157.08 million in FY 2023, reflecting a substantial rise that could pressure financial resources if not offset by revenue growth. (stockanalysis.com)
Immunocore's operating margin remains negative at -16.90% as of FY 2024, indicating ongoing challenges in achieving operational profitability. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

Immunocore Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Immunocore Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMCR

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs